Hudson Value Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.1M Sell
2,587
-14
-0.5% -$14.3K 0.78% 41
2026
Q1
$2.39M Sell
2,601
-181
-7% -$183K 0.71% 40
2025
Q4
$3M Buy
2,782
+12
+0.4% +$11.5K 0.89% 38
2025
Q3
$2.11M Buy
2,770
+321
+13% +$239K 0.65% 45
2025
Q2
$1.91M Sell
2,449
-25
-1% -$19.4K 0.66% 42
2025
Q1
$2.04M Buy
2,474
+1,102
+80% +$917K 0.77% 36
2024
Q4
$1.06M Hold
1,372
0.39% 56
2024
Q3
$1.22M Sell
1,372
-15
-1% -$13.5K 0.47% 51
2024
Q2
$1.26M Sell
1,387
-28
-2% -$22.4K 0.53% 50
2024
Q1
$1.1M Sell
1,415
-23
-2% -$16.4K 0.47% 56
2023
Q4
$838K Sell
1,438
-30
-2% -$17.5K 0.39% 62
2023
Q3
$789K Sell
1,468
-7
-0.5% -$3.61K 0.41% 62
2023
Q2
$692K Sell
1,475
-160
-10% -$67.1K 0.35% 65
2023
Q1
$561K Buy
1,635
+38
+2% +$12.8K 0.32% 69
2022
Q4
$584K Sell
1,597
-100
-6% -$35.5K 0.36% 70
2022
Q3
$549K Sell
1,697
-17
-1% -$5.39K 0.37% 66
2022
Q2
$556K Sell
1,714
-224
-12% -$67.2K 0.35% 69
2022
Q1
$555K Buy
1,938
+4
+0.2% +$1.03K 0.29% 79
2021
Q4
$534K Buy
1,934
+300
+18% +$76.1K 0.26% 80
2021
Q3
$378K Hold
1,634
0.21% 92
2021
Q2
$375K Hold
1,634
0.21% 92
2021
Q1
$305K Sell
1,634
-121
-7% -$23.7K 0.18% 93
2020
Q4
$293K Buy
+1,755
New +$262K 0.2% 94

Other funds holding LLY

Hudson Value Partners's LLY Position: Q2 2026 in Review

Hudson Value Partners reduced its Eli Lilly (LLY) stake by 0.54% in Q2 2026, selling an estimated $14.3K and leaving 2,587 shares worth $3.1M. The position accounts for 0.78% of the portfolio, ranked #41.

Hudson Value Partners first reported a position in LLY in Q4 2020 and has held it in 23 quarters since. 1,533 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Hudson Value Partners held 2,587 shares of Eli Lilly worth $3.1M as of Q2 2026.
  • Hudson Value Partners sold 14 Eli Lilly shares in Q2 2026, an estimated $14.3K.
  • Eli Lilly made up 0.78% of Hudson Value Partners's portfolio in Q2 2026, its #41 holding.
  • Hudson Value Partners first reported a position in Eli Lilly in Q4 2020 and has held it in 23 quarters since.
  • 1,533 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Hudson Value Partners's 13F filing for Q2 2026, filed 10 Jul 2026.